{"id":"NCT04140227","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)","officialTitle":"A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-24","primaryCompletion":"2022-01-05","completion":"2022-01-05","firstPosted":"2019-10-25","resultsPosted":"2023-12-29","lastUpdate":"2024-03-04"},"enrollment":256,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease (DED)"],"interventions":[{"type":"DRUG","name":"NOV03","otherNames":[]}],"arms":[{"label":"NOV03 4 times daily (QID)","type":"EXPERIMENTAL"}],"summary":"The objectives of this trial are to evaluate the safety and tolerability of perfluorohexyloctane (NOV03) ophthalmic solution during long-term use in subjects with Dry Eye Disease (DED) associated with MGD (Meibomian Gland Dysfunction).\n\nFurther objective is to evaluate the efficacy of perfluorohexyloctane (NOV03) solution during long-term use in subjects with DED associated with MGD.","primaryOutcome":{"measure":"Number of Participants With Ocular and Non-ocular Adverse Events","timeFrame":"12 months","effectByArm":[{"arm":"NOV03 4 Times Daily (QID)","deltaMin":69,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":28,"countries":["United States"]},"refs":{"pmids":["37921522"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":208},"commonTop":["COVID-19","Hypertension","Vitreous detachment","Conjuctivitis allergic","Lacrimation increased"]}}